Pharsight

Upsher Smith Labs patents expiration

1. Qudexy Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10363224 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(9 years from now)

US8652527 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(9 years from now)

US9555005 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(9 years from now)

US9101545 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(9 years from now)

US8889190 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(9 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 11 March, 2014

Treatment: Treatment of seizures

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of QUDEXY XR before it's drug patent expiration?
More Information on Dosage

QUDEXY XR family patents

Family Patents

2. Tosymra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8440631 UPSHER SMITH LABS Compositions for drug administration
May, 2026

(2 years from now)

US9283280 UPSHER SMITH LABS Compositions for drug administration
May, 2026

(2 years from now)

US8268791 UPSHER SMITH LABS Alkylglycoside compositions for drug administration
May, 2026

(2 years from now)

US11337962 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(6 years from now)

US10603305 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(6 years from now)

US9974770 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(6 years from now)

US9610280 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(6 years from now)

US9211282 UPSHER SMITH LABS Formulations comprising triptan compounds
Jul, 2031

(7 years from now)

Drugs and Companies using SUMATRIPTAN ingredient

Market Authorisation Date: 25 January, 2019

Treatment: Acute treatment of migraine

Dosage: SPRAY;NASAL

More Information on Dosage

TOSYMRA family patents

Family Patents

3. Vogelxo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295675 UPSHER SMITH LABS Testosterone gel compositions and related methods
Feb, 2034

(10 years from now)

US8785426 UPSHER SMITH LABS Testosterone gel compositions and related methods
Feb, 2034

(10 years from now)

US9662340 UPSHER SMITH LABS Testosterone gel compositions and related methods
Feb, 2034

(10 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 04 June, 2014

Treatment: Method for transdermal delivery of testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

More Information on Dosage

VOGELXO family patents

Family Patents

4. Zembrace Symtouch patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537554 UPSHER SMITH LABS Pharmaceutical composition for treating migraine
Jan, 2036

(12 years from now)

US11364224 UPSHER SMITH LABS Pharmaceutical composition for treating migraine
Jan, 2036

(12 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 28 January, 2016

Treatment: Treatment of migraine

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ZEMBRACE SYMTOUCH family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic